Evidence map›Paper›PMID 30358906›Full record

Trial reportCancer2018

Changes in body mass index, height, and weight in children during and after therapy for acute lymphoblastic leukemia.

Emily K Browne, Yinmei Zhou, Wassim Chemaitilly, John C Panetta, Kirsten K Ness, Sue C Kaste, Cheng Cheng, Mary V Relling, Ching-Hon Pui, Hiroto Inaba

Registry-linked trialOpen access · bronzeAbstract readClinical Trial
In one paragraph

Trial report in Cancer, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00137111 (Total XV - Total Therapy Study XV for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia), which is not on this map. Cited by 36 papers.

0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed
8.0field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00137111 phase3completednot on this map

Total XV - Total Therapy Study XV for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia

TypeinterventionalSponsorSt. Jude Children's Research HospitalRan2000 to 2014Enrolled501ConditionsLymphoblastic Leukemia, AcuteArmsPrednisone, Dexamethasone, Vincristine, Daunorubicin, Doxorubicin, L-asparaginase, PEG-L-asparaginase, Erwinia asparaginase, Methotrexate, Cyclophosphamide, Cytarabine, Etoposide, Mercaptopurine, Imatinib, chemotherapy, intrathecal chemotherapy
3 · Its place in the literature

Who cites it

36 citing papers in PubMed, 76 citations in OpenAlex.

  1. Exercise and QUality Diet after Leukemia: A Randomized Weight Loss Trial among Adult Survivors of Childhood Leukemia in the Childhood Cancer Survivor Study.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2024
    Trial
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. The evolution of nutritional care in children and young people with acute lymphoblastic leukaemia: a narrative review.Journal of human nutrition and dietetics : the official journal of the British Dietetic Association · 2025
    Review
  12. The Prevalence, Risk Factors and Cardiometabolic Complications of Obesity in Childhood Survivors of Acute Lymphoblastic Leukemia.Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion · 2024
    Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Emily K BrowneDepartment of Pediatric Medicine, St. Jude Children's Research Hospital, Memphis, Tennessee.
Yinmei ZhouDepartment of Biostatistics, St. Jude Children's Research Hospital, Memphis, Tennessee.
Wassim ChemaitillyDepartment of Pediatric Medicine, St. Jude Children's Research Hospital, Memphis, Tennessee.
John C PanettaDepartment of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, Tennessee.
Kirsten K NessDepartment of Epidemiology and Cancer Control, St. Jude Children's Research Hospital, Memphis, Tennessee.
Sue C KasteDepartment of Diagnostic Imaging, St. Jude Children's Research Hospital, Memphis, Tennessee.
Cheng ChengDepartment of Biostatistics, St. Jude Children's Research Hospital, Memphis, Tennessee.
Mary V RellingDepartment of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, Tennessee.
Ching-Hon PuiDepartment of Oncology, St. Jude Children's Research Hospital, Memphis, Tennessee.ORCID 0000-0003-0303-5658
Hiroto InabaDepartment of Oncology, St. Jude Children's Research Hospital, Memphis, Tennessee.ORCID 0000-0003-0605-7342
St. Jude Children's Research Hospital · US

Funding

Viral Vector Technology (VVTSR)P30CA021765 · NCI · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI Markos Leggas · 1985 to 2026
$166.9M
CPML - Project 3: Genome-wide Studies of Adverse EffectsP50GM115279 · NIGMS · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI RELLING, MARY V · 2015 to 2019
$15.1M
ALSACNCI NIH HHS CA21765NCI NIH HHS P30 CA021765NCI NIH HHS P50 GM115279NIGMS NIH HHS P50 GM115279
6 · The paper itself

Abstract

backgroundChildren with acute lymphoblastic leukemia (ALL) have an increased risk of obesity and short stature. To the authors' knowledge, data regarding patients treated on contemporary protocols without cranial irradiation are limited.

methodsChanges in z scores for body mass index (BMI), height, and weight from the time of diagnosis to 5 years off therapy were evaluated using multivariable analysis in 372 children with ALL who were aged 2 to 18 years at the time of diagnosis and were enrolled on the St. Jude Children's Research Hospital Total XV protocol from 2000 through 2007.

resultsThe percentage of overweight/obese patients increased from 25.5% at the time of diagnosis to approximately 50% during the off-therapy period. Median BMI z scores increased significantly during glucocorticoid therapy (induction: ∆0.56; 95% confidence interval [95% CI], 0.29-0.64 [P<.001]; and reinduction II: ∆0.22; 95% CI, 0.13-0.49 [P=.001]) and during the first year after therapy (∆0.18; 95% CI, 0.08-0.46 [P=.006]). Among patients who were of healthy weight/underweight at the time of diagnosis, those aged 2 to <10 years at diagnosis had a significantly higher risk of becoming overweight/obese during or after therapy compared with those aged ≥10 years (P=.001). Height z scores declined during treatment and improved after therapy. Being aged 2 to <10 years at the time of diagnosis, being of low-risk status, having a white blood cell count < 50×10

conclusionsThe results of the current study demonstrate that obesity is prevalent, and height growth, especially in patients with identified risk factors, appears compromised. Multidisciplinary intervention should begin during induction therapy and continue during the off-therapy period.

Indexed as

Body Mass IndexAdolescentAntineoplastic Combined Chemotherapy ProtocolsBody HeightBody WeightChildChild DevelopmentChild, PreschoolDexamethasoneDrug Administration ScheduleFemaleHumansLongitudinal StudiesMaleOverweightPediatric ObesityDexamethasonePrednisoneacute lymphoblastic leukemia (ALL)body mass index (BMI)childrenheightweight.

Identifiers

PMID30358906
PMCPMC6263845
OpenAlexW2898187866

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.